<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03521596</url>
  </required_header>
  <id_info>
    <org_study_id>FIL_BIOWM</org_study_id>
    <nct_id>NCT03521596</nct_id>
  </id_info>
  <brief_title>Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS</brief_title>
  <acronym>FIL_BIOWM</acronym>
  <official_title>Non-invasive Diagnostics and Monitoring of Minimal Residual Disease and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM Monoclonal Gammopathy of Undetermined Significance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter retrospective and prospective observational study including patients with WM or&#xD;
      IgM-MGUS evaluated at the time of diagnosis and during the disease course using highly&#xD;
      sensitive techniques.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter retrospective and prospective observational study including patients with WM or&#xD;
      IgM-MGUS evaluated at the time of diagnosis and during the disease course using highly&#xD;
      sensitive techniques such as flow cytometry, real time quantitative PCR (RT-qPCR), digital&#xD;
      droplet PCR (dd-PCR) and NGS, in order to: evaluate the mutational status on genomic DNA or&#xD;
      cell-free DNA and compare the results to assess the most reliable source for mutation&#xD;
      studies; perform and compare molecular and flow cytometry analyses on bone marrow, peripheral&#xD;
      blood (both analyses), plasma and urine samples (only molecular analysis) to assess the best&#xD;
      source for diagnosis and MRD monitoring.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 28, 2018</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Actual">October 6, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of mutation</measure>
    <time_frame>22 months</time_frame>
    <description>To demonstrate that the rate of mutations of MYD88 (L265P) and/or CXCR4 (S338X) detected in peripheral blood and/or urine show a negligible difference with the rate of mutations detected in bone marrow samples (BM, gold standard)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Patient enrolled</arm_group_label>
    <description>Part of the patients will be retrospectively enrolled (learning sample) and part prospectively (validation sample)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRD and clonal evolution</intervention_name>
    <description>Patient evaluation at the time of diagnosis and during the disease course using highly sensitive techniques</description>
    <arm_group_label>Patient enrolled</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood, Bone marrow and Urine collected at Baseline, Before treatment, after&#xD;
      treatment, at 12 months follow up and 24 months follow up&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include either IgM-MGUS, asymptomatic WM or symptomatic WM&#xD;
        patients requiring treatment. Patients in need of therapy will be treated according to&#xD;
        recently published guidelines [49]. Patients treated with new agents, including the BTK&#xD;
        inhibitor Ibrutinib, will be included. Patient enrolled retrospectively will constitute the&#xD;
        learning cohort of the study, while those enrolled prospectively will constitute the&#xD;
        validation cohort).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of IgM monoclonal gammopathy of undetermined significance (Ig-MGUS) or&#xD;
             Waldenström's Macroglobulinemia (WM) according to criteria established at the second&#xD;
             International Workshop on Waldenström's Macroglobulinemia [1]&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Previously untreated patients (only for the prospective cohort)&#xD;
&#xD;
          -  Symptomatic or asymptomatic disease&#xD;
&#xD;
          -  Subject understands and voluntarily signs an informed consent form approved by an&#xD;
             Independent Ethics Committee (IEC)/Institutional Review Board (IRB)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active HBV, HCV or HIV infection (antiHBc+ patients with undetectable HBV-DNA are&#xD;
             eligible to the study)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marzia Varettoni</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pavia - IRCCS Policlinico S. Matteo di Pavia - Div. di Ematologia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale Niguarda</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOS Ematologia Ospedale C. Massaia</name>
      <address>
        <city>Asti</city>
        <zip>14100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Tumori Giovanni Paolo II - UOC Ematologia</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Università degli Studi della Campania Luigi Vanvitelli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.R.C.C.S. Istituto Oncologico Veneto - Oncologia 1</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Arcispedale Santa Maria Nuova - IRCCS</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi di Rimini</name>
      <address>
        <city>Rimini</city>
        <zip>47924</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico A. Gemelli Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia, AOU Senese</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Città della Salute e della Scienza Ematologia Universitaria</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Integrata di Udine (A.S.U.I. Udine) - PO S. Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia - OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 30, 2018</study_first_submitted>
  <study_first_submitted_qc>April 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IgM monoclonal gammopathy</keyword>
  <keyword>Waldenström's Macroglobulinemia</keyword>
  <keyword>Minimal residual disease</keyword>
  <keyword>Clonal evolution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

